Taiwan-based MerryLife Biomedical announced positive Phase I results for TML-6, an innovative oral Alzheimer’s therapy designed to target multiple neurological pathways simultaneously. The investigational treatment demonstrated a favorable safety profile, positioning the company to advance into a global Phase 2 clinical trial targeting early-stage neurodegenerative disease.
TML-6 targets interconnected cellular processes that contribute to neurodegeneration. The molecule is designed to modulate the autolysosomal system, addressing critical biological mechanisms including protein clearance, neuroinflammation, oxidative stress, and age-related neuronal dysfunction.
By targeting multiple pathways simultaneously, TML-6 offers a potentially more comprehensive strategy compared to traditional single-target therapies and interrupt the complex cascade of events underlying neurological decline.
Clinical context
The company’s development plan for TML-6 includes a global Phase II clinical trial that will enroll approximately 210 participants across the United States, Sweden, and Taiwan, focused on individuals with mild cognitive impairment and mild dementia.
TML-6 is distinguished by its oral formulation and multi-targeted mechanism, potentially offering advantages in patient compliance and comprehensive disease management. The oral Alzheimer’s treatment market remains highly competitive, with several approaches under investigation:
- Nilotinib (Novartis): Targets autophagy and protein clearance
- Rapamycin: Focuses on mTOR pathway modulation
- COR588: applying gingipain inhibition strategies, under development by Quince Therapeutics (previously Cortexyme)
Beyond Alzheimer’s, MerryLife is exploring TML-6’s potential relevance in Parkinson’s disease, where similar pathological mechanisms contribute to neurological progression. The company plans to present additional preclinical data at the AD/PD 2026 International Conference in Copenhagen.